Semisynthetic antibody-antigen complexes:design, synthesis and kinetics by Lasonder, Edwin
  
 University of Groningen
Semisynthetic antibody-antigen complexes
Lasonder, Edwin
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
1995
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Lasonder, E. (1995). Semisynthetic antibody-antigen complexes: design, synthesis and kinetics. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
nalysis of monoclonal
I  system.  J .  Immunol .
I  which minimizes ide
ptide Protein Res. 36:
C.A.K. Borrebaeck.
:and. J. Immunol. 35:
and measurement of
-286.
Bell, and E.A. Buck-
rnal antibodies against
r acid substitution that





di jk, J.W. Dri j fhout,
,ntification of the core
lcoprotein D of herpes
rmunol. 24:3188-3 193.
ural definit ions. Res.
raches to the study of
(editor M.H.V. Van
'ijÍhout, W.J. Weijer,
I of glycoprotein D of
rnal antibodies. Arch.
ure of a herpes implex
7:562-568.
General discussion and summarY
The subject of this thesis is size reduction of antibody and antigen molecules to
small peptide molecules. In case of synthetic antigen-binding antibody fragments
(synthetic mini-antibodies) these peptides should be able to mimic the antibody
molecule in specific antigen-binding capacity, and in case of synthetic linear
epitopes these peptides should be able to mimic the antigen molecule in antibody-
recognition capacity. The demand on synthetic antibody fragments to maintain
antigen-binding capacity is much greater than the demand on synthetic epitopes
to maintain antibody-recognition capacity, because not all amino acid residues of
the antibody involved in antigen binding are available for interaction with
antigens. This in contrast to the interaction of antibodies with synthetic linear
epitopes.
Two approaches were used in the design of synthetic antibody fragments, which
are able to bind protein antigen molecules. The first approach was based on three-
dimensional structure information of the antibody-antigen complex of antibody
D1.3 and the protein antigen lysozyme. Surface Plasmon Resonance (SPR)
measurements howed that none of the tested peptides was able to bind lysozyme
in the same manner as monoclonal antibody D1.3. However, a 36-amino acid
residue peptide which contained two Complementarity Determining Regions
(CDRs) of the heavy chain of D1.3 was able to retard lysozyme in an
immunoaffinity chromatography study. This points to a weak interaction of this
peptide with lysozyme.
The second approach was a general procedure to develop synthetic antibody
fragments without prior knowledge about the three-dimensional structure of the
antibody-antigen complex. In this approach, all six CDRs were synthesized as
peptides and were tested for binding the antigen. The target antigen was
glycoprotein D of herpes simplex virus type 1. CDR-derived peptides of
monoclonal antibody A16 were synthesized and tested for binding glycoprotein
D by SPR measurements and by an immunoassay (ELISA). Peptides containing
two CDRs of the heavy chain of antibody Al6 and antibody Fdl38-80 were also
tested for binding glycoprotein D. It was not possible to synthesize CDR-derived
peptides which could bind the antigen glycoprotein D.
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These results strongly suggest, that there is no general way to obtain synthetic
mini-antibodies. Possible explanations for this are that the conformation of a
CDR-derived peptide is different from that in the antibody, or that the affinity of
a CDR-derived peptide is too low for detectable binding, or that antigen-binding
is achieved by cooperative binding of several CDRs. So far, the Fv fragment of
an antibody molecule is the shortest possible antigen-binding antibody fragment2,
because it possesses all six CDRs. In exceptional .ures''t-t it may be possible to
obtain smaller antibody fragments that are able to mimic the antibody-binding site.
The interaction between glycoprotein D of herpes simplex virus type I with MAb
A16 was also used in the study of the size reduction of an antigen molecule. A
previously identified linear epitope of glycoprotein D8 was shortened to its
minimal size, i.e. gD I l-17. SPR measurements howed that the binding constant
of this peptide with MAb A16 is similar to that of glycoprotein D. The
importance of the residues Asp-13, Arg-16 and Phe-17 for antibody binding was
shown by screening a phage display library with MAb A16 in a previous studya.
A 15-amino acid residue mimotope peptide was identified, which has residues
Asp-13, Arg-16 and Phe-17 in common with glycoprotein D. The contribution of
these residues to antibody binding was determined in a kinetic analysis with an
SPR biosensor. Kinetic parameters were determined of the interaction of MAb
A16 with gD 9-19 epitope peptides and gD 9-19 mimotope peptides. It appeared
that only one residue, i.e. Arg-16 is critical for binding and that two residues, i.e.
Asp-13 and Phe-17 contribute to the secondary structure (probably a B-turn) of
the gD 9-19 peptide. These two residues are contact residues as defined by
Getzoff et al.' Th" three residues mainly determine the strenglh of interaction
between gD and A16, because equal binding constants for gD 9-19 epitope and
gD 9-19 mimotope with MAb A16 were found.
In the reverse system, the interaction of a synthetic CDR-derived peptide with an
antigen, no specific binding could be achieved. A possible explanation for this
difference is that in case of synthetic mini-antibodies the large surface
complementarity between antibody and antigen is lost, while surface
complementarity is maintained in the interaction of synthetic epitope peptide with
an antibody. This explanation is also an important theoretical consideration for
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